Semaglutide effects: the reported benefits, the side effects, and the cautions

The short version

This page covers the human side of semaglutide and keeps two things clearly separate.

First: what people in the patient and clinical-use community report — quieter appetite, fewer cravings, weight coming off, better blood-sugar readings. These are real accounts gathered from patient-review sources. They align broadly with trial findings but they are firsthand stories, not controlled measurements, and no doses are attached. Treat them as anecdote.

Second: the cited clinical safety record — the gastrointestinal side effects that lead some people to stop, a boxed warning about a rare thyroid cancer, gallbladder risk, an eye-disease signal documented in SUSTAIN-6, lean-mass loss, and what happens to weight when semaglutide is stopped. These are trial findings and label statements, each cited.

Semaglutide is an FDA-approved prescription medicine. Nothing here constitutes a dose, a prescription, or a recommendation for any individual.

What people report

These are effects reported by people in patient-community sources — anecdotal, not clinical evidence, and not verified by controlled trials. They are kept separate from the cited clinical record below.

Benefits people describe most often

• A quieter relationship with food. By far the most common benefit reported is that the constant background attention to food — planning the next meal, thinking about snacks — diminishes, often within the first one to two weeks. People say they feel full faster, eat a third to a half of their usual portion, and stop obsessing over food between meals. Many call this the most meaningful change. Frequently reported.
• Reduced cravings (sugar, sweets, fried food). Sweet-tooth and sugar cravings drop sharply or disappear. Greasy and high-fat foods stop appealing — sometimes turning off-putting. People describe naturally gravitating toward lighter meals and fruit. Frequently reported.
• Sustained weight loss. The large majority of reviewers report substantial, steady weight loss over several months, tying it directly to eating much less. Frequently reported.
• Improved blood-sugar readings. Among people with type 2 diabetes, markedly improved fasting glucose and HbA1c averages are a common theme, with steadier energy through the day. Commonly reported.
• Reduced desire to drink alcohol. A recurring secondary observation is that the urge to drink fades alongside food cravings, with some people describing a simple loss of interest in alcohol. Occasionally reported.

Adverse effects people describe most often

• Nausea, sometimes with vomiting. The single most reported side effect, mentioned by roughly a third of reviewers. It peaks in the early weeks and after each dose increase, often easing within one to two weeks, and worsens after large or fatty meals. Frequently reported.
• Sulfur or "egg" burps. A distinctive complaint — foul-smelling belching compared to rotten eggs or sulfur, often arriving after a dose increase and sometimes lasting hours or days. Frequently accompanied by bloating and a sense of food sitting too long in the stomach. Many say it appears far more often than official lists suggest. Commonly reported.
• Bowel changes (constipation and diarrhea). Disrupted bowel habits are among the most mentioned digestive complaints, with both extremes reported, sometimes alternating. Commonly reported.
• Acid reflux and heartburn. Indigestion, reflux, and heartburn come up frequently alongside burping and bloating, tracking with dose increases. Occasionally reported.
• Early fatigue. Tiredness — especially in the first day or two after an injection and in the early weeks — is common, usually easing over time. Commonly reported.
• Food aversions and over-suppressed appetite. Beyond eating less, some people describe active aversions to fatty or meaty food, a metallic taste, and a heightened, often unpleasant sensitivity to smells likened to morning sickness. For a few, appetite is suppressed so far they must remind themselves to eat. Occasionally reported.
• Hair shedding and facial gauntness from rapid weight loss. Increased hair shedding (typically noticed a few months in) and a thinner, hollower face are reported by a smaller group — widely attributed to the pace of weight loss rather than the drug itself. Generally described as temporary. Sometimes reported.
• Headaches and dizziness. Often in the first days of a new dose; frequently linked to inadequate hydration or eating too little. Many say staying hydrated noticeably reduces them. Occasionally reported.
• Injection-site reactions. Mild redness, itching, a small bump, or tenderness where people inject — generally minor and short-lived. Sometimes reported.

Safety and cautions

This is the cited clinical safety record. Where a caution is a measured trial finding, it says so. Where it is a label warning, a pharmacovigilance signal, or a mechanism-based extrapolation, it says that too.

Gastrointestinal intolerance, worst during dose escalation. Nausea, vomiting, diarrhea, and constipation are the dominant adverse effects in clinical trials and the leading cause of discontinuation. In a pooled analysis of the STEP weight-management program these events were predominantly mild-to-moderate and transient, concentrated around the titration period ^[21]. A dedicated semaglutide safety review reported nausea in roughly one-third of patients ^[19], and real-world pharmacovigilance reporting is likewise dominated by gastrointestinal events ^[22]. The slowing of gastric emptying that underlies these effects is part of how the drug works — clinical, not theoretical.

Boxed thyroid warning (medullary thyroid carcinoma / MEN-2). GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors, derived from rodent studies at supratherapeutic exposures ^[18]. A dedicated assessment of thyroid carcinogenic risk concluded that available human data do not establish a clear increase in medullary or other thyroid cancer attributable to semaglutide; the signal should be described as unconfirmed in humans ^[18][19]. Even so, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN-2) is treated as a contraindication on the strength of the rodent data.

Acute pancreatitis (class warning). Acute pancreatitis is a recognized class warning, and treatment is conventionally stopped if pancreatitis is suspected. A dedicated semaglutide safety review notes that pancreatic-cancer signals cannot yet be resolved owing to low incidence rather than a confirmed association ^[19]. The caution is precautionary, not a demonstrated quantitative risk increase.

Gallbladder and biliary disease (cholelithiasis). The same safety review found an increased risk of gallstones (cholelithiasis, or gallstone formation) with semaglutide ^[19]. The effect is attributed largely to the rate and magnitude of weight loss rather than direct drug toxicity, but the increase versus placebo is a real clinical-trial and pharmacovigilance finding.

Pre-existing diabetic retinopathy with rapid glucose lowering. In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent with semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated among participants with pre-existing eye disease undergoing rapid HbA1c correction ^[1]. The leading interpretation is early worsening driven by speed of glycemic correction rather than direct retinal toxicity. Monitoring is advised when glycemia is corrected rapidly. This is a clinical-trial signal in people with diabetes.

Loss of lean (muscle) mass. A STEP-program body-composition substudy found that the weight lost with semaglutide comprised both fat and a meaningful proportion of lean mass ^[23]. Because rapid, large-magnitude weight loss can erode muscle — a particular concern in older adults — this has motivated research into adequate protein intake and resistance exercise. The lean-mass loss is an observed trial finding; the downstream sarcopenia (muscle-wasting) concern is a reasoned extrapolation.

Weight regain after stopping. In the STEP 1 trial extension, participants regained a mean of roughly 11.6 percentage points of body weight within one year of stopping, and cardiometabolic improvements reverted toward baseline ^[14]. The STEP 4 randomized-withdrawal design likewise documented regain after switching to placebo ^[24]. This frames obesity pharmacotherapy as a chronic rather than one-time intervention — the clinical-trial basis for long-term prescribing.

Hair shedding (telogen effluvium) with rapid weight loss. A pharmacovigilance analysis identified a reporting signal for alopecia (hair loss) with semaglutide ^[25], and a separate retrospective dermatology study linked telogen effluvium — a reversible, diffuse shedding — to the magnitude and rate of weight loss ^[26]. The signal is most consistent with rapid-weight-loss-associated shedding rather than direct drug toxicity.

Pregnancy: contraindicated, with a multi-week washout. Semaglutide is contraindicated in pregnancy per approved labeling. Because its elimination half-life is approximately one week — with effectively complete clearance only about five weeks after the last dose — the label advises stopping well in advance of a planned pregnancy, commonly cited as roughly two months ^[17]. The washout arithmetic is documented; the contraindication itself is a regulatory statement.

Oral formulation requires strict fasted administration. Oral semaglutide is co-formulated with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, a compound that promotes gastric absorption) and has very low oral bioavailability (~0.4-1%), so it must be taken on an empty stomach with only a small amount of plain water, at least 30 minutes before food, other drinks, or other oral medications ^[27]. Administration errors can substantially reduce absorbed dose. This is a formulation requirement, not a toxicity.

Narrow-therapeutic-index oral drugs during titration. A systematic review of drug-drug interactions between GLP-1 receptor agonists and oral medications found that delayed gastric emptying generally does not produce clinically significant interactions, but recommended monitoring for narrow-therapeutic-index drugs — medications whose effective range is close to the toxic range — especially during dose escalation ^[28]. The overall interaction risk is characterized as low.

Then and now

Semaglutide is the product of Novo Nordisk's incretin-peptide chemistry, built on earlier GLP-1 analogue work and engineered for once-weekly dosing through DPP-4 resistance and albumin-binding fatty-acid acylation ^[17]. It first reached FDA approval for type 2 diabetes in 2017, with an oral once-daily tablet following in 2019-2020 and a chronic weight-management indication in 2021 ^[2][1]. Its cardiovascular-outcomes evidence read out in SUSTAIN-6 (in diabetes) ^[1] and SELECT (in non-diabetic obesity) in 2023 ^[3]; the kidney-outcomes evidence followed in FLOW in 2024 ^[4]; and a metabolic dysfunction-associated steatohepatitis (MASH) indication followed from the ESSENCE trial in 2025 ^[11]. During a federally declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to produce semaglutide; that compounding pathway was curtailed once the shortage was declared resolved in 2025 ^[3].